Literature DB >> 11768292

Ways to fit a PK model with some data below the quantification limit.

S L Beal1.   

Abstract

Pharmacokinetic data consist of drug concentration measurements, as well as reports of some measured concentrations being below the quantification limit of the assay (BQL). A pharmacokinetic model may befit to these data, and for this purpose, the BQL observations must be either discarded or handled in a special way. In this paper, seven methods for dealing with BQL observations are evaluated. Both single-subject and population data are simulated from a one-compartment model. A moderate amount of data is simulated for each individual. The actual cv of concentration measurements at the quantification limit is assumed to be no greater than 20%, in accord with the FDA Guidance. The results of this paper should be interpreted in this context. The methods include handling BQL observations as fixed-point censored observations, i.e., by using the likelihoods that these observations are in fact BQL. This method is shown to have some overall statistical advantage. However, the gain in using this method over that of simply discarding the BQL observations is not always much, and this is especially so when the frequency of BQL observations is small. Some simple methods entailing (i) replacing one or more BQL observations with the value 0, or (ii) replacing them with the value QL/2, where QL is the quantification limit, are also included. The first of these two approaches should not be used With population data, use of the second approach can result in some noticeably improved estimation of the typical value of a parameter, but then there is also marked degradation in the estimation of the population variance of the parameter.

Mesh:

Year:  2001        PMID: 11768292     DOI: 10.1023/a:1012299115260

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  1 in total

1.  Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Authors:  J Lu; J M Gries; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

  1 in total
  428 in total

1.  Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.

Authors:  Christelle Rodrigues; Catherine Chiron; Elisabeth Rey; Olivier Dulac; Emmanuelle Comets; Gérard Pons; Vincent Jullien
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

2.  Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.

Authors:  Christopher M Rubino; Alan Forrest; Sujata M Bhavnani; Gary Dukart; Angel Cooper; Joan Korth-Bradley; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

3.  Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.

Authors:  Hanna E Silber; Claudia Burgener; Ingrid M Letellier; Mathieu Peyrou; Martin Jung; Jonathan N King; Philippe Gruet; Jerome M Giraudel
Journal:  Pharm Res       Date:  2010-10-05       Impact factor: 4.200

4.  WebPK, a web-based tool for custom pharmacokinetic simulation.

Authors:  Jaydeep Srimani; Richard A Moffitt; May D Wang
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2010

5.  First-dose pharmacokinetics of lithium carbonate in children and adolescents.

Authors:  Robert L Findling; Cornelia B Landersdorfer; Vivian Kafantaris; Mani Pavuluri; Nora K McNamara; Jon McClellan; Jean A Frazier; Linmarie Sikich; Robert Kowatch; Jacqui Lingler; Jon Faber; Perdita Taylor-Zapata; William J Jusko
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

6.  Increased clearance of morphine in sickle cell disease: implications for pain management.

Authors:  Deepika S Darbari; Michael Neely; John van den Anker; Sohail Rana
Journal:  J Pain       Date:  2011-02-01       Impact factor: 5.820

7.  Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.

Authors:  Vincent Duval; Mats O Karlsson
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

8.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

9.  Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.

Authors:  Weirong Wang; Xiaofeng Wang; Rajitha Doddareddy; Damien Fink; Thomas McIntosh; Hugh M Davis; Honghui Zhou
Journal:  AAPS J       Date:  2013-11-28       Impact factor: 4.009

10.  Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.

Authors:  Iñaki F Trocóniz; Josep-María Cendrós; Concepción Peraire; Joaquim Ramis; Maria J Garrido; Paolo F Boscani; Rosendo Obach
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.